Pitcairn Co. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,770 shares of the company’s stock after buying an additional 124 shares during the period. Pitcairn Co.’s holdings in IDEXX Laboratories were worth $442,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in the company. Williams Jones & Associates LLC acquired a new position in IDEXX Laboratories during the second quarter valued at about $61,058,000. Fiera Capital Corp acquired a new position in IDEXX Laboratories during the second quarter valued at about $43,771,000. Fundsmith LLP boosted its position in IDEXX Laboratories by 6.1% in the second quarter. Fundsmith LLP now owns 4,469,336 shares of the company’s stock valued at $415,023,000 after buying an additional 258,657 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in IDEXX Laboratories during the second quarter valued at about $22,338,000. Finally, Prudential Financial Inc. boosted its position in IDEXX Laboratories by 439.0% in the third quarter. Prudential Financial Inc. now owns 293,466 shares of the company’s stock valued at $33,082,000 after buying an additional 239,020 shares during the last quarter. Institutional investors own 91.39% of the company’s stock.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down 0.98% during midday trading on Wednesday, reaching $141.73. The company had a trading volume of 897,313 shares. The company’s 50 day moving average is $122.08 and its 200-day moving average is $113.90. The company has a market capitalization of $12.66 billion, a P/E ratio of 58.09 and a beta of 0.48. IDEXX Laboratories, Inc. has a 52-week low of $66.82 and a 52-week high of $143.47.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.07. The company had revenue of $443 million for the quarter, compared to analysts’ expectations of $436.07 million. IDEXX Laboratories had a negative return on equity of 671.57% and a net margin of 12.51%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 earnings per share. Equities analysts expect that IDEXX Laboratories, Inc. will post $2.93 earnings per share for the current fiscal year.
IDXX has been the topic of several recent analyst reports. Zacks Investment Research cut IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, January 16th. Canaccord Genuity set a $125.00 target price on IDEXX Laboratories and gave the stock a “buy” rating in a research report on Monday, January 23rd. Finally, Feltl & Co. cut IDEXX Laboratories from a “hold” rating to a “sell” rating in a report on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $123.50.
In other news, Chairman Jonathan W. Ayers sold 27,424 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, November 29th. The stock was sold at an average price of $119.77, for a total transaction of $3,284,572.48. Following the sale, the chairman now owns 1,001,043 shares of the company’s stock, valued at $119,894,920.11. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Thomas Craig sold 8,500 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $120.06, for a total value of $1,020,510.00. Following the sale, the director now directly owns 32,783 shares in the company, valued at approximately $3,935,926.98. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 49,112 shares of company stock worth $5,881,972. Corporate insiders own 2.79% of the company’s stock.
IDEXX Laboratories Company Profile
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).